Objective: To examine the cardiovascular effects of combined amylin (AMN) and leptin (LEP) treatment in lean and obese rats. Research design: Rats were instrumented for telemetry and given LEP (300 mg kg -1 day -1 ), AMN (100 mg kg -1 day -1 ), AMN þ LEP or vehicle (VEH; 0.9% normal saline) via a subcutaneous mini-osmotic pump for 7 days. The VEH group was subdivided into ad libitum fed and pair-fed to the amount of food AMN þ LEP animals ate daily. Rats were housed in metabolic chambers for analysis of cardiovascular physiology and metabolism. Subjects: Male Fisher 344 Â Brown Norway (FBNF1; Harlan; age ¼ 3-5 months; n ¼ 72) rats were placed on standard rodent chow (LEAN, n ¼ 41) or moderately high-fat diet (OBESE; n ¼ 31) to produce obesity. Results: AMN þ LEP potently reduced food intake (LEAN: 57% OBESE: 59%) and abdominal fat mass (LEAN: 56% OBESE: 41%). Pair-fed rats displayed bradycardia and metabolic suppression. In contrast, AMN þ LEP increased heart rate and oxygen consumption above levels in LEP or AMN-treated rats. LEP reduced blood pressure in both lean and obese rats but AMN had no effect. LEP-induced reductions in blood pressure were not altered by AMN þ LEP treatment. Thus, AMN þ LEP treatment decreased food intake, body fat and blood pressure in lean and obese rats. Conclusion: We conclude that the potent anti-adiposity actions of AMN þ LEP are due in part to prevention of the bradycardia and metabolic suppression typically observed with negative energy balance. Furthermore, the hypotensive actions of peripheral LEP treatment are observable in spite of the potent AMN þ LEP activation of anorexic and thermogenic mechanisms in the central nervous system.
Introduction
Preclinical and clinical studies have convincingly demonstrated a potent and synergistic action of amylin (AMN) and leptin (LEP) in treating obesity. [1] [2] [3] [4] It is likely that central nervous system pathways contribute to AMN and LEP regulation of appetite and energy expenditure. 5 It is now well established that these central nervous system pathways also have important actions on the cardiovascular system. 6, 7 For example, patients with obesity because of melanocortin 4 receptor mutations have a low incidence of hypertension while acute infusion of melanocortin 4 receptor agonists increases blood pressure. 8 Clearly, the cardiovascular effects of anti-obesity drugs must be well understood. 9 Although studies have been conducted to understand the anorectic role of AMN and LEP separately in relation to food intake, there is little information concerning the combined cardiovascular actions of these hormones. Central LEP is sympathoexcitatory and can increase blood pressure.
10, 11 However, supraphysiological peripheral doses are generally required for marginal increases in blood pressure, and some studies report that lower levels of LEP either have no effect on or lower blood pressure. [12] [13] [14] [15] Less is known about the cardiovascular actions of AMN. In general, acute studies have suggested that AMN produces vasodilation via calcitonin gene-related peptide receptor activation. 16 A recent clinical study reported that chronic treatment with synthetic AMN (pramilintide) decreases blood pressure in obese human subjects, while subjects treated with the combination of AMN and sibutramine or phentermine lost more weight, but did not have a beneficial decrease in blood pressure. 17 Here, we hypothesized that the combination of LEP and AMN treatment might produce significant reductions in blood pressure. The goal of this study was to determine the cardiovascular and metabolic actions of combined LEP and AMN in lean and obese rats.
Materials and methods

Animals and housing
Male Fisher 344 Â Brown Norway (FBNF1; Harlan, Indianapolis, IN, USA; Age ¼ 3-5 months; n ¼ 72) rats were placed on standard rodent chow (Labdiet 5001, LabDiets, Richmond, IN, USA; 4.5% fat), and housed individually at Ta ¼ 23 1C on a 12-h light-dark cycle. This rat strain was selected because on reaching adulthood, the FBNF1 rat maintains a relatively stable plateau of body weight gain when fed ad libitum unlike obesityprone strains, which display continuous body weight gain.
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After 2 weeks recovery from transport, 31 FBNF1 rats were placed on a moderately high-fat diet (Research Diets D12266B, Research Diets, Inc., New Brunswick, NJ, USA; 32% fat) for 5 months to induce obesity. The remaining 41 FBNF1 rats were maintained on standard chow and prepared for study shortly after reaching a stable body weight above 300-350 g. The apparatus and procedures used for determination of energy expenditure and locomotor activity have been described previously. 19, 20 Briefly, rats were housed in individual polycarbonate 20 l cages each fitted for open circuit respirometry. Oxygen consumption and carbon dioxide production were continuously measured 23 h day -1 . Beneath each cage is a custom-designed force platform to obtain precise quantification of locomotor activity and a telemetry receiver that collects the transmitted blood pressure data. Metabolic and cardiovascular data are monitored continuously and stored for offline analysis.
Surgery
All FBNF1 rats were implanted with cardiovascular telemetry devices (TA11PA-C40; DSI, St Paul, MN, USA) as described previously. 20 After surgery, animals were given subcutaneous injections of 30 mg kg -1 buprinex analgesic (Henry Schein Inc., Melville, NY, USA) and intramuscular injections of 60 mg kg -1 of cefazolin (Henry Schein Inc.) as a prophylactic.
Rats were then re-housed individually at Ta ¼ 23 1C on a 12-h light-dark cycle and their previously assigned diet and allowed to recover at least 10-day before experimentation.
LEP, AMN and AMN þ LEP infusion in lean and obese rats After acclimation to metabolic chambers (3-4 days), and baseline cardiovascular and metabolic data collection (2-3 days), 7-day osmotic pumps were implanted in the intrascapular region under light halothane anesthesia. Baseline data representing a 2-to 3-day average for all experimental groups are displayed in ), both AMN þ LEP or saline vehicle (VEH; 0.9% NaCl, 10 ml h -1 ). The VEH group was subdivided into those fed ad libitum (VEH) and those that were pair-fed to the amount of food AMN þ LEP animals ate daily (PF AMN þ LEP). All animals received their food just before the onset of the dark phase. On the seventh day of infusion, animals were terminated for post-mortem analysis as described below.
Post-mortem dissection and serum hormone analysis Rats were anesthetized with pentobarbital (50 mg kg -1 , intraperitoneally). All animals were killed just at the end of the light cycle. Trunk blood was obtained by decapitation and blood was stored temporarily at 4 1C for centrifugation. Blood was spun at 3000 Â g for 15 min at 4 1C; supernatant serum was removed and stored at À20 1C for determination of LEP and AMN concentrations. The remaining carcass was dissected for heart, kidney, retroperitoneal, mesenteric and epididymal abdominal fat pad weights. LEP hormone analysis was performed using a radioimmunoassay kit for rat LEP (RL-83K; Linco; St Charles, MO, USA). AMN hormone analysis was done using a radioimmunoassay kit for rat/mouse AMN (RK-017-11; Phoenix Pharmaceuticals; Burlingame, CA, USA). Both assays were performed according to their respective manufacturers' protocols.
Data management
During the last hour of the light phase, animals, food and water were weighed daily. At this time, all data from the previous day were transferred for offline analysis. In order to quantify the effects of infusion between groups, these data were expressed as differences from each animal's average baseline values, combined by treatment group, and reported as daily means±s.e.m.
Oxygen consumption (VO 2 ), carbon dioxide production (VCO 2 ), mean arterial pressure and heart rate (HR) were measured continuously throughout the days of baseline and infusion. Respiratory quotient (RQ), an index of substrate utilization, was calculated as the ratio of VCO 2 /VO 2 . Higher RQ values indicate increased utilization of carbohydrates over fat and vice versa. 21 VO 2 was analyzed after normalization to the Kleiber coefficient to account for differences in metabolic mass. [22] [23] [24] [25] In order to quantify the effects of infusion between groups, these continuously measured parameters were separated into 12-h dark and 11-h light phase daily means and expressed as differences from each animal's average baseline values. These 'delta values' were combined by treatment group and reported as daily means ± s.e.m. In order to present data in concise format, only dark phase data for all metabolic and both dark and light phase data for cardiovascular parameters are shown, however, the observed effects were similar in both light and dark phases.
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Statistical analysis
Using Sigmastat 3.1 (Systat Software Inc., Chicago, IL, USA), mean differences were analyzed using two-way repeated measures analysis of variance (repeated measure ¼ time (days) Â treatment group) to evaluate effects of drug treatments over time for most dependent variables. Tukey's post hoc tests were used to determine specific days in which treatment groups are significantly different from one another. For terminal single-value measurements such as serum LEP or fat pad weights, a one-way analysis of variance for treatment group and a Tukey's post hoc test was used.
Ethical approval
All of the procedures were approved and authorized by the Animal Care and Use Committee at Florida State University.
Results
Potent inhibition of food intake and prevention of metabolic suppression in lean and obese rats Animals consuming a 32% fat diet had greater body weight (Table 1) , serum LEP and AMN levels ( Table 2) and Table 1 Baseline parameters for lean and obese FBNF1 rats Amylin þ leptin lowers blood pressure and body fat R Seth et al abdominal body fat ( Figure 4 ) and thus were considered obese. Chronic LEP infusion produced a significant decrease in food intake in lean (21%) but not obese rats (Figures 1a  and d) . Chronic AMN infusion reduced food intake in both lean (24%) and obese (30%) rats (Figures 1b and e) . Further, infusion of AMN with LEP significantly reduced food intake in both lean (57%) and obese (59%) rats (Figures 1c and f) . All the food intake values mentioned above are percentage differences based on 7-day food intake average of VEHtreated group. In lean animals, neither LEP nor AMN maintain VO 2 at the level of VEH-treated ad lib rats (Figures 2a and b) although they did prevent the suppression in VO 2 associated with pair feeding (data not shown). In obese animals, there was no effect of AMN or LEP on VO 2 (Figures 2d and e) . AMN þ LEP in both lean and obese rats completely prevented the metabolic suppression associated with an even greater reduction in food intake and maintained VO 2 compared with controls (Figures 2c and f) . The suppressive effect of such a reduction in food intake is evident in the pair-fed group to AMN þ LEP-treated rats.
Synergistic reductions in fat mass with AMN and LEP in lean and obese rats LEP modestly reduced RQ in lean but not obese rats (Figures 3a and d) . AMN, on the other hand, decreased RQ in lean rats but only modestly reduced RQ in obese rats (Figures 3b and e) . In both lean and obese rats, AMN þ LEP produced a sustained decrease in RQ that was significantly greater than VEH, pair-fed controls, and either treatment alone (Figures 3c and f) . In obese animals, abdominal fat Amylin þ leptin lowers blood pressure and body fat R Seth et al AMN þ LEP: 10.1±0.7 g) OBESE: (LEP: 21.3±1.8 g AMN: 19.2 ± 2.4 g AMN þ LEP: 14.7 ± 1.6 g PF AMN þ LEP: 21.7 ± 1.3 g)) There were no significant effects of any treatments on heart and kidney weights in these animals.
Cardiovascular effects of AMN and LEP
Neither LEP nor AMN increased HR in lean animals in dark phase (Figures 5a and b) or light phase (Figures 6a and b) . In obese rats, LEP increased HR but AMN had no effect in dark phase (Figures 5d and e) or light phase (Figures 6d and e) . AMN þ LEP significantly increased HR above controls in obese rats only. In both lean and obese animals, AMN þ LEP prevented the bradycardia associated with pair feeding in dark (Figures 5c and f) as well as light phase (Figures 6c and  f) . LEP reduced blood pressure in both lean and obese rats in dark (Figures 7a and d ) and light phase (Figures 8a and d) . AMN had no effect on blood pressure in either lean or obese animals in dark (Figures 7b and e 
Effects of treatments on serum hormone levels
The effects of different treatments on the serum concentrations of AMN and LEP are depicted in Table 2 . In lean rats, LEP and AMN þ LEP increase serum LEP as expected. Amylin þ leptin lowers blood pressure and body fat R Seth et al AMN treatment reduced serum LEP likely because of decreased food intake and fat mass, as seen in pair-fed rats (data not shown). Serum LEP was not significantly different between LEP and AMN þ LEP rats. Similarly, serum AMN was not significantly different between AMN and AMN þ LEP rats.
Rats consuming a high-fat diet and infused with saline had elevated LEP and AMN level, consistent with increased abdominal fat mass. LEP treatment in obese animals increased serum LEP above controls despite no effect on food intake or fat mass. On the other hand, AMN þ LEP treatment did not increase serum LEP above controls Amylin þ leptin lowers blood pressure and body fat R Seth et al possibly because of large reductions in fat mass leading to decreased endogenous LEP production. AMN þ LEP did prevent the drop in serum LEP seen in pair-fed rats. Again, in obese animals, AMN treatment and AMN þ LEP treatment raised serum AMN above all other groups but not significantly different from one another.
Discussion
Similar to several recent reports, 26 we observed that the combination therapy of AMN þ LEP produced potent reductions in food intake and adiposity in both lean and obese rodents. Furthermore, the combination therapy completely prevented the metabolic suppression associated with weight loss in both lean and obese rats. It is commonly observed that caloric restriction-induced metabolic suppression is associated with bradycardia. Here again, we observed that the combination therapy effectively prevented this suppression of HR in both lean and obese rats. Finally, we replicated previous findings indicating subcutaneous LEP infusion lowers blood pressure, while AMN alone did not significantly alter blood pressure. When combined, AMN þ LEP decreased blood pressure well below the response observed in pair-fed animals suggesting a primary effect rather than a secondary consequence of weight loss.
AMN-LEP actions on food intake, energy expenditure and lipolysis Chronic AMN decreases food intake in lean and obese rats. 1, 27 However, the anorectic effects of chronically infused AMN subside quickly. At the dose of subcutaneous AMN used in this study, we observed a loss of anoretic efficacy within a few days of infusion. It is well documented that rats made obese by consuming higher amounts of fat in their diet are resistant to the anorectic actions of LEP. 28, 29 The mechanisms by which this occurs include both humoral adaptations 30, 31 and inhibitory mechanisms at the cellular and neuronal level. 32, 33 Our experiments confirm that 5 months of 32% fat diet-induced resistance to the anorectic effects of LEP. However, the combination treatment with AMN þ LEP circumvented this resistance producing potent reductions in food intake that after 1 week were greater than the sum of the response produced by individual AMN or LEP treatments. Throughout the baseline and treatment periods, all rats studied in these experiments were housed in home cage calorimeters for assessment of energy expenditure. We observed no significant thermogenic effects of LEP or AMN when given individually; however, pair-fed animals exhibited reductions in metabolic rate (data not shown). Thus, either LEP or AMN can prevent caloric restriction-induced metabolic suppression. The physiologic responses to mild pair feeding are well understood, 12 and thus we chose not to verify this response for LEP and AMN groups. Rats pair-fed fed to the low levels of food intake produced by AMN þ LEP (Figures 2c and f) displayed potent metabolic suppression. We observed that combination therapy with AMN þ LEP completely prevented this metabolic suppression and tended to increase energy expenditure.
We assessed lipolysis by continuously measuring RQ and by post-mortem fat pad weights after 1 week of therapy. Amylin þ leptin lowers blood pressure and body fat R Seth et al AMN produced a transient suppression of RQ in both lean and obese rats, while LEP produced a decrease in RQ that was only evident in lean rats. When combined, AMN þ LEP produced a substantial reduction in RQ that was clearly sustained for the week of treatment. As a result, the combination treatment produced substantial, reductions in fat pad mass. Further studies are warranted to determine the duration of these appetite-suppressing, thermogenic and lipolytic effects and the mechanisms that drive this unabated persistence of negative energy balance. One interpretation of these responses is that the AMN appears to increase LEP sensitivity in obese animals. It has been reported that AMN and LEP synergistically increase LEP receptor expression in adipose tissue and liver. 34 Chronic AMN þ LEP also reduces expression of lipogenic genes and increases expression of lipolytic genes in adipose tissue, while either LEP or AMN in monotherapy has no effect. 3 AMN þ LEP may also act to increase LEP signaling in hypothalamic nuclei. 34 Within the hypothalamus, AMN suppresses expression of orexigenic neurohormones normally increased during caloric restriction 35, 36 and upregulates anorectic neuronal signals. 1, 37 Interestingly, these signaling pathways overlap with downstream LEP signaling in the hypothalamus and are implicated in the anorexigenic and metabolic effects of LEP. Further, the resistance mechanisms such as elevated suppressor of cytokine signaling-3 (Bjorbaek et al. 38 ; Peralta et al.
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) or reduced LEP receptor expression 40 by which LEP is rendered ineffective may be altered by AMN signaling or as a consequence of AMNs anorectic effects. 41 Taken together, these findings suggest a potential modulatory role for AMN in regulation of LEP effects on food intake and adiposity.
Cardiovascular effects of LEP persist during AMN co-infusion LEP can both increase 11, 42, 43 ) of LEP decrease food intake without increasing blood pressure, 15 suggesting a differential sensitivity for the anorectic and sympathetic actions of LEP. Additionally, LEP can act peripherally at a number of sites including the vasculature 48 possibly contributing to observed depressor actions of peripheral LEP. 45 LEP stimulates nitric oxide production, a vasodilator from vascular endothelial cells and vascular smooth muscle, both in vitro 45, 49 and in vivo.
12,44
We observed that chronic, peripheral AMN monotherapy at a dose that appears to augment LEP action of feeding and lipolysis in rats does not alter blood pressure. However, AMN alone did prevent the bradycardia associated with caloric restriction (Figures 5 and 6 ) consistent with a previous report of a cardioacceleratory effect. 50 Further, AMN did not alter the depressor effects of physiological hyperleptinemia when AMN þ LEP was given. By contrast, in a recent clinical trial, AMN-induced weight loss was associated with the expected reduction in blood pressure long term and had no effect on HR. When combined with the sympathoexcitatory weight loss drug phentermine, AMN produced greater weight loss, along with an increase in both HR and blood pressure. 17 It appears inevitable that combination therapies will become common in the treatment of obesity. The results of this study suggest the possibility that AMN þ LEP treatment may decrease both body fat and blood pressure. If observed in clinical trials, this response would represent a promising step forward in the effort to develop effective drug therapy for obesity without undesired cardiovascular side effects. 9 
Conflict of interest
The authors declare no conflict of interest.
